Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) |
||
| Line 27: | Line 27: | ||
===Regimen {{#subobject:#30ab57|Variant=1}}=== | ===Regimen {{#subobject:#30ab57|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| − | !Study | + | !style="width: 33%"|Study |
| − | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
| − | ![[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full Willis et al. 2001] | |[https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full Willis et al. 2001] | ||
Revision as of 02:39, 19 August 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
2 regimens on this page
2 variants on this page
|
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
Relapsed or refractory
Alemtuzumab monotherapy
| back to top |
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Willis et al. 2001 | Phase II | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains verified protocol PubMed
Sirolimus monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Bride et al. 2015 | Phase II |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
- See manuscript for recommended dose adjustments
6-month course, extended for those with a favorable response
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains protocol PubMed